MZF1 and neoplasm: The MZF1 immunoreactivity was significantly higher in gastric cancer cases with deeper gastric wall invasion (P < 0.001), lymph node metastasis (P < 0.001), distant metastasis (P = 0.029), and advanced tumor-node-metastasis (TNM) stage (P < 0.001) (Supplementary Table S1).